Alexion Pharmaceuticals (ALXN) Earns Buy Rating from Leerink Swann
Leerink Swann reaffirmed their buy rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research report report published on Wednesday morning. The brokerage currently has a $169.00 price objective on the biopharmaceutical company’s stock.
A number of other equities analysts have also recently issued reports on the company. TheStreet cut Alexion Pharmaceuticals from a b- rating to a c+ rating in a report on Friday, November 10th. Zacks Investment Research cut Alexion Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, November 1st. Royal Bank Of Canada upped their target price on Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Stifel Nicolaus lowered their target price on Alexion Pharmaceuticals from $165.00 to $159.00 and set a buy rating for the company in a report on Tuesday, October 24th. Finally, Piper Jaffray Companies reaffirmed an overweight rating and issued a $170.00 target price on shares of Alexion Pharmaceuticals in a report on Monday, October 23rd. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $154.49.
Alexion Pharmaceuticals (ALXN) opened at $114.46 on Wednesday. Alexion Pharmaceuticals has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. The stock has a market capitalization of $23,855.68, a PE ratio of 21.84, a price-to-earnings-growth ratio of 1.16 and a beta of 1.18.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The business had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $864.34 million. During the same quarter in the prior year, the firm earned $1.23 EPS. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. equities analysts forecast that Alexion Pharmaceuticals will post 4.82 earnings per share for the current year.
Several institutional investors have recently made changes to their positions in ALXN. Fiduciary Trust Co. bought a new stake in shares of Alexion Pharmaceuticals during the 2nd quarter valued at about $111,000. Valeo Financial Advisors LLC bought a new stake in shares of Alexion Pharmaceuticals during the 3rd quarter valued at about $147,000. Penserra Capital Management LLC boosted its position in shares of Alexion Pharmaceuticals by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 144 shares in the last quarter. Dupont Capital Management Corp bought a new stake in shares of Alexion Pharmaceuticals during the 3rd quarter valued at about $156,000. Finally, Acadian Asset Management LLC bought a new stake in shares of Alexion Pharmaceuticals during the 2nd quarter valued at about $160,000. Institutional investors own 94.16% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.